Arteaus_portfolio

Arteaus Therapeutics

In December 2013 Eli Lilly and Company (NYSE:LLY) acquired all development rights for Arteaus Therapeutics’ calcitonin gene-related peptide (CGRP) antibody upon the completion of a Phase 2a clinical trial for the prevention of frequent, recurrent migraine headaches.

Headquarters Cambridge, MA
Website www.arteaus.com‚Äč
Pipeline Multiple Phase 2b trials in progress at Lilly